Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric vedolizumab IV maintenance study in Crohn's disease
2020-004301-31Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in Crohn's disease (2 arms), sponsored by Takeda. Primary endpoint: Clinical remission at Week 54. Started Apr 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2020-004301-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004301-31.